Journal of Cancer Research and Clinical Oncology

, Volume 137, Issue 2, pp 287–293 | Cite as

Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma

  • Clovis O. da Fonseca
  • Marcela Simão
  • Igor R. Lins
  • Regina O. Caetano
  • Débora Futuro
  • Thereza Quirico-Santos
Original Paper

Abstract

Purpose

The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients.

Patients and methods

It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment.

Results

Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression.

Conclusion

Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.

Keywords

Glioblastoma Perillyl alcohol Terpene Intranasal administration Tumor topography 

References

  1. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156:529–536PubMedGoogle Scholar
  2. Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:2267–2273CrossRefPubMedGoogle Scholar
  3. da Fonseca CO, Landeiro JA, Clark SS, Quirico-Santos T, da Costa Carvalho MG, Gattass CR (2006a) Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg Neurol 65(Suppl 1):S1:2–S1:8 (discussion S1:8–1:9)Google Scholar
  4. da Fonseca CO, Masini M, Futuro D, Caetano R, Gattass CR, Quirico-Santos T (2006b) Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review. Surg Neurol 66:611–615CrossRefPubMedGoogle Scholar
  5. da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T (2008a) Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz) 56:267–276CrossRefGoogle Scholar
  6. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, Gattass CR (2008b) Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70:259–266 (discussion 266–257)CrossRefPubMedGoogle Scholar
  7. da Fonseca CO, Silva JT, Lins IR, Simao M, Arnobio A, Futuro D, Quirico-Santos T (2009) Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs 13:557–564CrossRefGoogle Scholar
  8. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S, Kuo MD (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA 105:5213–5218CrossRefPubMedGoogle Scholar
  9. Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C (2008) Histological and molecular classification of gliomas. Rev Neurol (Paris) 164:505–515Google Scholar
  10. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69:9065–9072CrossRefPubMedGoogle Scholar
  11. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH 2nd, Deen DF (2008) New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 10:112–120CrossRefPubMedGoogle Scholar
  12. Heimberger AB, Suki D, Yang D, Shi W, Aldape K (2005) The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3:38–43CrossRefPubMedGoogle Scholar
  13. Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells–potential partners in glioma drug resistance? Cancer Treat Rev 34:558–567CrossRefPubMedGoogle Scholar
  14. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1:44–51PubMedGoogle Scholar
  15. Lefranc F, Facchini V, Kiss R (2007) Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12:1395–1403CrossRefPubMedGoogle Scholar
  16. Rainov NG, Soling A, Heidecke V (2006) Novel therapies for malignant gliomas: a local affair? Neurosurg Focus 20:E9PubMedGoogle Scholar
  17. Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ (2006) Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res 66:7067–7074CrossRefPubMedGoogle Scholar
  18. Sathornsumetee S, Rich JN (2008) Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 1142:108–132CrossRefPubMedGoogle Scholar
  19. Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG, Borghesi S, Martinelli F, Bordi L, Ammannati F, Biti G (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19:613–620CrossRefPubMedGoogle Scholar
  20. Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63:162–169CrossRefPubMedGoogle Scholar
  21. van Genugten J, Leffers P, Baumert B, Tjon-a-Fat H, Twijnstra A (2010) Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol 96:249–257CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Clovis O. da Fonseca
    • 1
    • 2
  • Marcela Simão
    • 3
  • Igor R. Lins
    • 2
  • Regina O. Caetano
    • 3
  • Débora Futuro
    • 4
  • Thereza Quirico-Santos
    • 3
  1. 1.Departamento de Cirurgia Geral e EspecializadaUnidade de Pesquisa Clínica, Hospital Universitário Antonio PedroNiteróiBrazil
  2. 2.Department of General and Specialized SurgeryClinical Research Unit - Antonio Pedro University Hospital, Fluminense Federal UniversityNiteróiBrazil
  3. 3.Laboratory of Cellular Pathology, Department of Cellular and Molecular BiologyInstitute of Biology, Fluminense Federal UniversityNiteróiBrazil
  4. 4.Department of Pharmaceutical SciencesSchool of Pharmacy, Fluminense Federal UniversityNiteróiBrazil

Personalised recommendations